Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk National University Medical School, 634-18, Keum-Am Dong, Jeonju 561-712, Republic of Korea.
J Diabetes Res. 2013;2013:631218. doi: 10.1155/2013/631218. Epub 2013 Mar 12.
DA-9801, a mixture of extracts from Dioscorea japonica Thunb. and Dioscorea nipponica Makino, was reported to have neurotrophic activity. Therefore, we investigated the therapeutic potential of DA-9801, in comparison with alpha lipoic acid (ALA), for peripheral nerves preservation in experimental diabetes. Experimental animals were divided into 4 groups, and each group was designated according to the type of treatment administered as follows: normal, DM, DM+DA-9801, and DM+ALA. After 16 weeks, response thresholds to tactile and thermal stimuli were higher in DM+DA-9801 group than in nontreated DM group. This degree of increase in DM+DA-9801 group indicates more therapeutic potency of DA-9801 than ALA. Western blot analysis showed more significant increase in NGF and decrease in TNF-α and IL-6 in DM+DA-9801 group than in DM or DM+ALA groups (P < 0.05). IENF density was reduced less significantly in the DM+DA-9801 group than in other DM groups (7.61 ± 0.32, 4.2 ± 0.26, and 6.5 ± 0.30 in DM+DA-9801, DM, and DM+ALA, resp., P < 0.05). Mean myelinated axonal area in the sciatic nerves was significantly greater in DM+DA-9801 group than in other DM groups (69.2 ± 5.76, 54.0 ± 6.32, and 63.1 ± 5.41 in DM+DA-9801, DM, and DM+ALA, resp., P < 0.05). Results of this study demonstrated potential therapeutic applications of DA-9801 for the treatment of diabetic peripheral neuropathy.
DA-9801 是从薯蓣属植物（Dioscorea japonica Thunb. 和 Dioscorea nipponica Makino）的提取物混合物，具有神经营养活性。因此，我们研究了 DA-9801 对实验性糖尿病周围神经保护的治疗潜力，并与α-硫辛酸（ALA）进行了比较。实验动物分为 4 组，根据给予的治疗类型进行分组，具体如下：正常组、糖尿病组、糖尿病+DA-9801 组和糖尿病+ALA 组。16 周后，糖尿病+DA-9801 组的触觉和热刺激反应阈值高于未治疗的糖尿病组。与 ALA 相比，DA-9801 组的这种增加程度表明 DA-9801 具有更强的治疗效果。Western blot 分析显示，与糖尿病组或糖尿病+ALA 组相比，糖尿病+DA-9801 组的 NGF 显著增加，TNF-α 和 IL-6 显著减少（P<0.05）。糖尿病+DA-9801 组的 IENF 密度减少程度明显低于其他糖尿病组（7.61±0.32、4.2±0.26 和 6.5±0.30，分别为糖尿病+DA-9801、糖尿病和糖尿病+ALA 组，P<0.05）。与糖尿病组或糖尿病+ALA 组相比，糖尿病+DA-9801 组坐骨神经中髓鞘化轴突面积显著增加（69.2±5.76、54.0±6.32 和 63.1±5.41，分别为糖尿病+DA-9801、糖尿病和糖尿病+ALA 组，P<0.05）。本研究结果表明，DA-9801 具有治疗糖尿病周围神经病变的潜在治疗应用。
